Non-Insulin Dependent Diabetes Mellitus (NIDDM) and Angiotensin Converting Enzyme 2 (ACE2): Diabetic Patients Treated With Antihypertensive Drugs

Phase 4UnknownNCT00192803

Rambam Health Care Campus20 enrolled

Overview

This feasibility study is designed to examine modulation of the relative activities of ACE and ACE2 in diabetic patients following treatment with the angiotensin type 1 receptor (AT1R) antagonist, Candesartan. This study will provide a closer insight to the possible involvement of the renin-angiotensin system (RAS)-related enzymatic components in development or attenuation of vascular pathogenesis.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

ECT

Masking

NONE

Enrollment

Conditions

NIDDM

Interventions

candesartanDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Signed informed consent * Non-smokers * Type II DM diagnosed patients * Blood pressure \< 135/90 * Serum HbA1C \> 7% * Serum creatinine \< 1mg% * Urine microalbumin \< 300 mg/day * Body mass index (BMI) \< 35 kg/m2 Exclusion Criteria: * Insulin-dependent diabetic patients * Patient with persistent microalbuminuria * Patient with history of severe hypertension * Congestive heart failure * Patient receiving renin-angiotensin-aldosterone system (RAAS)-related anti-hypertensive medications. * Patient with major hepatic disease

Locations (1)

Internal Ward "A", Rambam Medical Center

Haifa, Israel

Outcomes

Primary Outcomes

ACE and ACE2 activities in monocytes

Central Contacts

Shlomo Keidar, MD

CONTACT

97248542518 skeidar@rambam.health.gov.il

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.